ArchiveJanuary 2015

B cells: treatment effects on B cells may hold the clue to progressive MS

Natalizumab vs. Alemtuzumab: effects on B cells in the brain and spinal cord are different. #MSBlog #MSResearch “Natalizumab vs. alemtuzumab: yesterday someone asked the question about why would anyone choose natalizumab over alemtuzumab? I have posted on this topic before and it essentially comes down to choice; a philosophical question about a treatment strategy.” “A large...

B cell depletion in progressive MS appears to be marginal

Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One. 2013 ;8(7):e66308 BACKGROUND:Rituximab is an anti-CD20 monoclonal antibody approved for non Hodgkin lymphoma and rheumatoid arthritis. It is being considered for the treatment of MS.OBJECTIVES:To evaluate the efficacy and safety of...

Does having MS affect your children?

Razaz N, Tremlett H, Boyce WT, Guhn M, Joseph K, Marrie RA. Impact of parental multiple sclerosis on early childhood development: A retrospective cohort study. Mult Scler. 2015. pii: 1352458514559298. [Epub ahead of print] BACKGROUND:Exposure to parental chronic illness is associated with several adverse developmental outcomes.OBJECTIVES: We examined the association between parental multiple...

ClinicSpeak: natalizumab PML update – Q4 2014

December 2014 natalizumab PML update: underestimating the PML risk? #ClinicSpeak #MSBlog #MSResearch “The following are the latest risk figures for PML as a result of being treated with natalizumab. Please note that the embedded slideshow is for health professionals only; if you are not a health professional Biogen-Idec don’t want you to see this presentation. If you are a MSer...

HSCT vs. Alemtuzumab: is it time for a head-2-head study?

Have your say and help design a clinical trial? #MSBlog #MSResearch “In view of the current interest in HSCT I have made a first attempt at designing a trial to ascertain whether or not HSCT (hematopoietic stem cell transplantation) is non-inferior to alemtuzumab. The latter is the only realistic way of powering the study. For this to be developed into a protocol each section needs work...

Japanese MSers accumulate less disability

Piccolo L, Kumar G, Nakashima I, Misu T, Kong Y, Wakerley B, Ryan S, Cavey A, Fujihara K, Palace J. Multiple sclerosis in Japan appears to be a milder disease compared to the UK. J Neurol. 2015 Jan 22. [Epub ahead of print] Multiple sclerosis (MS) is relatively common in the West, but rare in Japan. In the literature, there are few comparative data regarding disease severity throughout...

Placebo and Nocbo effects

Bittar C, Nascimento OJ. Placebo and nocebo effects in the neurological practice.Arq Neuropsiquiatr. 2015 Jan;73(1):58-63. doi: 10.1590/0004-282X20140180. Epub 2015 Jan 1 Knowledge of placebo and nocebo effects is essential to identify their influence on the results in clinical practice and clinical trials, and thereby properly interpret their results. It is known that the gold standard of...

IS timing of Optic Neuritis eye damage and slow treatment why drugs are showing no effect

Gabilondo I, Martínez-Lapiscina EH, Fraga-Pumar E, Ortiz-Perez S, Torres-Torres R, Andorra M, Llufriu S, Zubuizarreta I, Saiz A, Sanchez-Dalmau B, Villoslada P.Dynamics of retinal injury after acute optic neuritis. Ann Neurol. 2015 Jan. doi: 10.1002/ana.24351. [Epub ahead of print] Background: We set out to assess the dynamics of retinal injury after acute optic neuritis (ON), and their...

Nerve loss in childhood MS

Why is paediatric MS so much worse than adult MS? #MSBlog #MSResearch “The pathology study below suggests that acute MS lesions in children with MS are more damaging that those that are found in adults. The number of transected, cut or shredded, axons (nerve processes) was 50% greater in inflammed MS lesions from children compared to lesions from adults. This may explain why children with...

Translate

Categories

Recent Posts

Recent Comments

Archives